WESPAC Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-12,720
| Closed | -$1.9M | – | 153 |
|
|
2023
Q3 | $1.9M | Buy |
12,720
+593
| +5% | +$87.1K | 1.42% | 17 |
|
|
2023
Q2 | $1.63M | Sell |
12,127
-614
| -5% | -$90K | 1.31% | 21 |
|
|
2023
Q1 | $2.03M | Buy |
+12,741
| New | +$1.95M | 1.91% | 13 |
|
|
2022
Q4 | – | Sell |
-11,722
| Closed | -$1.57M | – | 64 |
|
|
2022
Q3 | $1.57M | Sell |
11,722
-5,341
| -31% | -$766K | 2.12% | 11 |
|
|
2022
Q2 | $2.61M | Buy |
17,063
+7,690
| +82% | +$1.18M | 1.99% | 11 |
|
|
2022
Q1 | $1.52M | Sell |
9,373
-5,220
| -36% | -$758K | 1.64% | 17 |
|
|
2021
Q4 | $1.98M | Buy |
14,593
+156
| +1% | +$18.4K | 1.32% | 16 |
|
|
2021
Q3 | $1.56M | Buy |
14,437
+8,256
| +134% | +$943K | 0.96% | 30 |
|
|
2021
Q2 | $696K | Sell |
6,181
-7,134
| -54% | -$803K | 1.33% | 26 |
|
|
2021
Q1 | $1.44M | Sell |
13,315
-3,845
| -22% | -$411K | 1.08% | 25 |
|
|
2020
Q4 | $1.84M | Buy |
+17,160
| New | +$1.65M | 1.42% | 10 |
|
|
2020
Q1 | – | Sell |
-15,555
| Closed | -$1.38M | – | 50 |
|
|
2019
Q4 | $1.38M | Sell |
15,555
-1,826
| -11% | -$152K | 1.35% | 33 |
|
|
2019
Q3 | $1.32M | Sell |
17,381
-10,532
| -38% | -$722K | 1.31% | 33 |
|
|
2019
Q2 | $2.03M | Buy |
+27,913
| New | +$2.19M | 1.51% | 29 |
|
|
2019
Q1 | – | Sell |
-32,170
| Closed | -$2.97M | – | 126 |
|
|
2018
Q4 | $2.97M | Buy |
+32,170
| New | +$2.83M | 2.88% | 3 |
|
|
2018
Q1 | – | Sell |
-18,466
| Closed | -$1.79M | – | 146 |
|
|
2017
Q4 | $1.79M | Sell |
18,466
-1,178
| -6% | -$111K | 1.66% | 20 |
|
|
2017
Q3 | $1.75M | Sell |
19,644
-1,264
| -6% | -$96.2K | 1.15% | 31 |
|
|
2017
Q2 | $1.52M | Buy |
20,908
+7,735
| +59% | +$520K | 1.04% | 37 |
|
|
2017
Q1 | $858K | Sell |
13,173
-2,396
| -15% | -$151K | 0.99% | 39 |
|
|
2016
Q4 | $975K | Buy |
15,569
+545
| +4% | +$33.3K | 1.09% | 38 |
|
|
2016
Q3 | $948K | Buy |
15,024
+2,345
| +18% | +$152K | 1.07% | 37 |
|
|
2016
Q2 | $785K | Buy |
+12,679
| New | +$773K | 0.81% | 44 |
|
|
2015
Q3 | – | Sell |
-40,028
| Closed | -$2.69M | – | 65 |
|
|
2015
Q2 | $2.69M | Buy |
40,028
+4,394
| +12% | +$287K | 2.02% | 10 |
|
|
2015
Q1 | $2.09M | Buy |
35,634
+610
| +2% | +$36.9K | 1.58% | 19 |
|
|
2014
Q4 | $2.29M | Buy |
35,024
+5,691
| +19% | +$359K | 1.61% | 19 |
|
|
2014
Q3 | $1.69M | Buy |
+29,333
| New | +$1.63M | 1.36% | 22 |
|
|
2014
Q1 | – | Sell |
-16,095
| Closed | -$850K | – | 135 |
|
|
2013
Q4 | $850K | Buy |
16,095
+9,479
| +143% | +$466K | 0.71% | 61 |
|
|
2013
Q3 | $296K | Buy |
+6,616
| New | +$293K | 0.35% | 94 |
|
Other funds holding ABBV
WESPAC Advisors's ABBV Position: Q4 2023 in Review
WESPAC Advisors sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 12,720 shares — an estimated $1.9M sold.
WESPAC Advisors first reported a position in ABBV in Q3 2013 and held it in 28 quarters. The position peaked at $2.97M in Q4 2018. 3,323 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.
- WESPAC Advisors reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
- WESPAC Advisors sold 12,720 AbbVie shares in Q4 2023, an estimated $1.9M.
- WESPAC Advisors first reported a position in AbbVie in Q3 2013 and held it in 28 quarters.
- WESPAC Advisors's AbbVie position peaked at $2.97M in Q4 2018.
- 3,323 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.
Based on WESPAC Advisors's 13F filing for Q4 2023, filed 26 Jan 2024.